1. Home
  2. AMBO vs APRE Comparison

AMBO vs APRE Comparison

Compare AMBO & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ambow Education Holding Ltd.

AMBO

Ambow Education Holding Ltd.

HOLD

Current Price

$2.33

Market Cap

7.2M

Sector

Real Estate

ML Signal

HOLD

Logo Aprea Therapeutics Inc.

APRE

Aprea Therapeutics Inc.

HOLD

Current Price

$0.94

Market Cap

8.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMBO
APRE
Founded
2000
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.2M
8.4M
IPO Year
2010
2019

Fundamental Metrics

Financial Performance
Metric
AMBO
APRE
Price
$2.33
$0.94
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$4.10
AVG Volume (30 Days)
10.7K
308.7K
Earning Date
08-05-2025
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
337.04
21.22
EPS
0.02
N/A
Revenue
$9,469,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$100.42
N/A
Revenue Growth
0.82
N/A
52 Week Low
$1.47
$0.55
52 Week High
$6.75
$2.22

Technical Indicators

Market Signals
Indicator
AMBO
APRE
Relative Strength Index (RSI) 55.18 63.79
Support Level $1.60 $0.90
Resistance Level $2.43 $0.98
Average True Range (ATR) 0.28 0.09
MACD 0.03 0.03
Stochastic Oscillator 69.25 91.00

Price Performance

Historical Comparison
AMBO
APRE

About AMBO Ambow Education Holding Ltd.

Ambow Education Holding Ltd is an AI-driven technology educational company. Along with its subsidiaries, the company is developing a new HybriU AI Digital Education Solution that transforms the educational environment, bridging the gap between traditional methods and the future of digital learning. The solution combines sophisticated software and hardware to create an AI-powered digital and hybrid classroom, designed to enhance educational delivery and engagement. In addition, the group offers high-quality, individualized, and dynamic career education services and products through the operation of its for-profit colleges. Substantially the majority of the group's revenues are derived from the United States, based on the geographical locations where services are provided to customers.

About APRE Aprea Therapeutics Inc.

Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.

Share on Social Networks: